Acquisition Overview - Danaher has agreed to acquire Masimo for $9.9 billion to enhance its diagnostics franchise [1] - The acquisition will allow Masimo to operate as a standalone business unit within Danaher's diagnostics portfolio [1] Strategic Fit - Masimo's advanced sensor technology and AI-enabled monitoring will add significant capabilities to Danaher's diagnostics offerings [2] - The deal, priced at $180 per share, has received unanimous approval from both companies' boards [2] Leadership and Transition - The acquisition follows the resignation of Masimo's CEO Joe Kiani after a conflict with activist investor Politan Capital Management [3] - Katie Szyman, the new CEO of Masimo, believes the partnership with Danaher will enhance the global scalability of Masimo's technologies [3] Value Proposition - Masimo's board evaluated various opportunities and concluded that the transaction with Danaher was the most beneficial for all stakeholders [4] - Masimo is projected to contribute high-single-digit core revenue growth long-term, with expected EBITDA exceeding $530 million by 2027 [5] Timeline and Conditions - The acquisition is expected to close in the second half of 2026, subject to regulatory approvals and other closing conditions [5]